COVID-RED

COVID-19 infections - remote early detection

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 21
Grant agreement number
101005177

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
9 592 029
EFPIA in kind
737 225
Total Cost
10 329 254

Summary

Could digital technologies help to detect COVID-19 cases? The COVID-RED project thinks so – it aims to assess how wearable devices and mobile apps could pick up on potential cases before people start to feel unwell.

It is well known that people with COVID-19 are highly infectious in the 48 hours before they develop symptoms. A key element in COVID-RED’s plans is an Ava bracelet, a wearable device typically used by women to track their fertility. The bracelet is equipped with sensors to measure things like the user’s breathing rate, pulse and skin temperature, which could change slightly before the user actually starts to feel ill.

The bracelet will sync with a mobile app that will detect any unusual variation in these parameters. The app will also allow users to report any symptoms, as well as any factors that could influence the bracelet’s findings, such as having drunk alcohol or the use of medicines to reduce fever.

Based on all this input, an algorithm would provide the user with real-time feedback on the likelihood of infection, and whether or not the user should self-isolate or seek medical advice (for a potential COVID test or for further care, for example).

COVID-RED will test its system on 13 000 people from the general population, plus 7 000 people from high risk groups. In parallel, a group of the same size will be equipped with just the app, but no bracelet. At the end of the study, all participants will be tested for COVID-19 antibodies.

Achievements & News

Participants Show participants on map

EFPIA companies
  • Roche Diagnostics Nederland BV, Almere, Netherlands
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Stichting Sanquin Bloedvoorziening, Amsterdam, Netherlands
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • University College London, London, United Kingdom
  • Vive - Det Nationale Forsknings- Og Analysecenter For Velfaerd, Copenhagen, Denmark
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ava AG, Zurich, Switzerland
  • Julius Clinical Research BV, Zeist, Netherlands
  • Labormedizinosches Zentrum Dr Rischostschweiz AG, Buchs, Switzerland
Third parties
  • Labormedizinisches Zentrum Dr Rischservices AG, Buchs, Switzerland
Project coordinator
Diederick Grobbee
Universitair Medisch Centrum Utrecht